Summary.-Enhancement of CCNU cytotoxicity by misonidazole (MISO) was studied in three tumours and two normal tissues in the mouse.
alkylating agents by misonidazole (1-[2-nitromidazole-1 -yl] -3 -methoxypropan -2-ol) (MISO) has been reported for several mouse tumour systems by many authors (Rose et al., 1980; Tannock, 1980; Clement et al., 1980; Martin et al., 1981; Law et al., 1981; Siemann, 1981; Stephens et al., 1981; Twentyman et al., 1981; AMulcahy et al., 1981) . Most of these studies have shown that, at least under some circumstances, MISO is more effective in increasing the cytotoxicity of chemotherapeutic agents to tumours than to normal tissues, thereby giving a positive therapeutic gain, though there is no clear consensus as to the mechanisms involved.
Particularly dramatic enhancement has been reported for the combination of the nitrosourea CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) and MISO in the KHT sarcoma (Siemann, 1981 ). An enhancement of up to 2-4 was obtained, which, compared with a value of 1-4 for normal-tissue toxicity assessed by the LD50/30 assay, leads to a "therapeutic gain" of 1-7-1 8. An aim of the experiments described here was to determine whether this encouraging result could be obtained in other tumours, and whether the low enhancement of normal-tissue toxicity holds when more specific and clinically relevant end-points than LD50/30 are used.
The principal dose-limiting toxicity of CCNU in man is delayed leucopenia due to the killing of marrow stem cells. However, following the use of CCNU in the treatment of the more curable cancers such as Hodgkin's disease, an otherwise successful outcome is often complicated by long-term sterility in male patients. The responses of marrow stem cells and testis were, therefore, selected as clinically relevant endpoints for the assessment of normal-tissue in the present study.
MATERIALS AND METHODS

Tumour systems
Three mouse tumour lines were used in the present experiments: EMT6/St/lu tumour (Brown & Workman, 1980) , the SCCVJI/St carcinoma and the KHT sarcoma (Kallman et al., 1967 were found but in no experiment was the incidence greater than 0 3 colonies per spleen.
Testis.-The cell-cycle kinetics of spermatogenesis in the mouse testis have been studied extensively (Oakberg, 1956; Meistrich et al., 1978) . While the response of spermatogonial stem cells will determine long-term sterility, this population in the testis of the mouse shows considerable resistance to most chemotherapeutic agents. The survival of the more sensitive differentiated spermatogonia was therefore used as an end-point in the present study. It has been shown (Lu & Meistrich, 1979 ) that the number of sperm heads in testis homogenates 29 days after drug treatment reflects the sensitivity of differentiated spermatogonia to that treatment. The same technique was used in the present experiments except that the testis homogenates were not sonicated before sperm-head counting, because excellent reproducibility has been obtained without this procedure.
Drug treatments
All drug solutions for injection were prepared immediately before injection. Misonidazole (MISO) and SR-2508(N-(2-hydroxyethyl)-2-(2-nitro-1-imidazolyl)acetamide) were dissolved in sterile saline at a concentration of 25 mg/ml and 80 mg/ml, respectively, in most experiments. CCNU was dissolved in peanut oil (Eastman Kodak) at concentrations of 1, 2 or 4 mg/ml, depending on the drug dose to be administered. MISO and CCNU were injected i.p., whereas SR-2508 was injected into a tail vain. In experiments requiring "simultaneous" injection of MISO and CCNU, MISO was always given immediaely before CCNU into the opposite side of the abdomen.
RESULTS
Tumours CCNU dose responses.-Previously published data (Siemann, 1981) Fig. 3 . In the case of marrow stem cells (Fig. 3a, b The effect of MISO dose on marrow stem cells and testis spermatogonia at a constant simultaneous dose of CCNU is shown in Fig. 4 . As the dose of MISO increased, progressively more enhancement of CCNU cytotoxicity was found. This relationship is very similar to that for the tumours.
Mechanisms
In our previous study of the enhancement of cyclophosphamide cytotoxicity by MISO (Law et al., 1981 ) metabolic effects were excluded as the principal mechanism of interaction. We have tested the possible importance of an effect of MISO on CCNU metabolism and pharmacokinetics in the following experiments.
The effect of SR-2508 on CCNU cytotoxicity was investigated. The radiosensitizer SR-2508, a 2-nitroimidazole of similar electron affinity and radiosensitizing efficiency to MISO is less toxic and not appreciably metabolized in vivo (Workman & Brown, 1981) . Furthermore, it does not cause a drop in body temperature, as seen in mice after MISO (Law et al., 1981) . Fig. 5 shows the effect of SR-2508 on cell survival after CCNU in the KHT tumour. SR-2508 did not enhance the cytotoxicity of CCNU. after drug injection is shown in Fig. 6 . In showed the SCCVII/St tumour (Fig. 6a) (Fig. 7) . Only in the KHT tumour was there any increase in survival, but even then survival decreased with time after injection up to 6 h. However, there results should not be interpreted as excluding the possibility of PLD repair. Some repair may occur which is masked by the declining survival. As shown in Fig. 6 , the dominant trend was for survival to decrease as the interval between injection of drug and tumour excision was increased. This effect might reasonably be attributed to continued cell killing by CCNU metabolites remaining in the circulation of the aniimal; enhancement by MISO would then reflect an effect on CCNU metabolism which increases the yield of toxic species. This view was reinforced by the observation that the radiosensitizer SR-2508 had no effect on the sensitivity of the KHT tumour to CCNU (Fig. 5) . SR-2508 is similar to MISO in its sensitizing efficiency and electron affinity , but unlike MISO it is not extensively metabolized in vivo. The lack of effect of SR-2508 might suggest that metabolism of the radiosensitizer is necessary for chemosensitization, but it does not exclude other mechanisms.
There is evidence from other studies to suggest that another explanation of MISO enhancement of CCNU toxicity may be more attractive. Decreasing survival has been shown to occur over several hours after a 1 h exposure of mammalian cell in vitro to CCNU and subsequent removal of the drug (Barranco et al., 1975) . It seems reasonable to infer that decreasing survival would occur in vivo by a similar mechanism not requiring the presence of the drug or its metabolites. Some insight into the nature of this process is provided by Ewig & Kohn (1978) . Alkaline elution experiments have shown that cross-links are formed between opposing strands of the DNA of cells treated with CCNU, and that this process occurs slowly over several hours, even after the drug has been removed. These results are entirely consistent with our own observations of the slow development of lethal lesions in tumour cells treated in vivo with CCNU. Experiments are now in progress, using the alkaline-elution assay, to determine whether MISO increases the yield of these DNA cross-links or inhibits the systems responsible for their repair. CONCLUSIONS 1. Mouse tumours show great differences in their sensitivity to CCNU.
2. In all the tumours investigated, MISO enhanced CCNU cytotoxicity.
3. The resistant tumour showed enhancement only at high doses where the doselimiting normal tissue was equally sensitized.
4. Sensitive tumours showed enhancement at lower CCNU doses where there was no sensitization by MISO of the cytotoxicity to marrow stem cells.
5. If sterility is considered to be an important factor in the treatment outcome, it should be noted that spermatogonia were sensitized by MISO almost as much as the tumours, at all CCNU doses.
